Annovis Bio Inc. announced on June 26, 2025, that its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place from July 27–31, 2025, in Toronto, Canada. The company plans to present four scientific posters at this event. These presentations will highlight advances in the Alzheimer’s clinical program.
The posters will also cover the pharmacokinetic characterization of its lead drug candidate, buntanetap. Presenters will include Cheng Fang, Ph.D., Senior Vice President, Research & Development; Sarah MacCallum, Director of Clinical Operations; Alexander Morin, Ph.D., Director of Strategic Communications; and Matthew Peterson, Ph.D., Senior Clinical Scientist.
The AAIC is the world’s largest meeting dedicated to advancing the science and clinical practice of dementia. This participation underscores Annovis's commitment to sharing its research and engaging with the global scientific community on its progress in neurodegenerative disease therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.